NCT04283513

Treatment of Hemorrhagic Fever With Ribavirin

Treatment Protocol for Adults With Hemorrhagic Fever With Renal Syndrome (HFRS) With Intravenous (IV) Ribavirin

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: U.S. Army Medical Research and Development Command · Federal
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Multisite protocol to provide IV Ribavirin treatment to patients with probable or suspected case of Hemorrhagic Fever with Renal Syndrome (HFRS)

Detailed description

This protocol is an open-label, single-arm, multisite protocol to provide IV ribavirin treatment to patients with probable or suspected case of HFRS. Individuals with a tentative diagnosis of HFRS will be admitted to the MTF and treated for up to 7 days with doses of IV ribavirin.

Conditions

• Hemorrhagic Fever

Interventions

Type	Name	Description
DRUG	Virazole	Virazole (Ribavirin), USP Injection 0.1 g/mL in a phosphate buffer solution. Each vial contains 1.2 g of Ribavirin in 12 mL

Timeline

• Start date: 2022-10-31
• Primary completion: 2026-04-01
• Completion: 2027-07-01
• First posted: 2020-02-25
• Last updated: 2025-06-25

Locations

1 site across 1 country: Germany